• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Mirum Pharmaceuticals, Inc. - common stock (NQ:MIRM)

    114.72 +3.65 (+3.29%)
    Streaming Delayed Price Updated: 2:18 PM EDT, Jun 24, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Mirum Pharmaceuticals, Inc. - common stock

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    13 14 Next >
    News headline image
    Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
    From Mirum Pharmaceuticals, Inc. and Incyte
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026
    From Mirum Pharmaceuticals, Inc. and Incyte
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Dips After Q1 Revenue Beat and Guidance Raise, Despite Massive IPR&D Charge ↗
    Via Chartmill
    News headline image
    Mirum Pharmaceuticals Enters Catalyst-Rich Stretch as LIVMARLI Sales and Pipeline Advance ↗
    Mirum Pharmaceuticals (NASDAQ:MIRM) executives said the rare disease company is entering a catalyst-heavy period, with recent positive clinical updates, ongoing commercial momentum for LIVMARLI and... 
    Via MarketBeat
    News headline image
    Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharma: A Rare Disease Growth Story to Watch ↗
    Mirum stock pulled back after earnings despite strong growth. Here’s why investors still see upside in the rare disease biotech company 
    Via MarketBeat
    News headline image
    Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Penn Capital Unloads 1.13 Million RealReal Shares Following Massive Stock Run-Up ↗
    This online marketplace connects U.S. consumers with consigned luxury goods, spanning apparel, jewelry, art, and home products. 
    Via The Motley Fool
    Topics Artificial Intelligence Regulatory Compliance
    News headline image
    Mirum (MIRM) Q1 2026 Earnings Call Transcript ↗
    Mirum (MIRM) Q1 2026 Earnings Call Transcript 
    Via The Motley Fool
    Topics Earnings
    News headline image
    Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    2 Under-the-Radar Biotech Stocks Worth Buying for the Long Term ↗
    Vertex Pharmaceuticals has given Mirum Pharmaceuticals the blueprint for success in rare diseases. 
    Via The Motley Fool
    News headline image
    Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Prediction: Buying This Biotech Stock Today Could Set You Up for Life ↗
    This small biotech could grow much larger with some good news from its pipeline. 
    Via The Motley Fool
    News headline image
    Mirum (MIRM) Q2 2025 Earnings Call Transcript ↗
    Mirum (MIRM) Q2 2025 Earnings Call Transcript 
    Via The Motley Fool
    Topics Earnings
    News headline image
    Mirum Pharma (MIRM) Earnings Call Transcript ↗
    Mirum Pharma (MIRM) Earnings Call Transcript 
    Via The Motley Fool
    Topics Earnings
    News headline image
    Mirum (MIRM) Q1 2025 Earnings Call Transcript ↗
    Mirum (MIRM) Q1 2025 Earnings Call Transcript 
    Via The Motley Fool
    Topics Earnings Intellectual Property
    News headline image
    Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026 ↗
    This clinical-stage biotech develops precision therapies for genetically defined diseases, targeting rare cancers and systemic mastocytosis. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position ↗
    This biotech firm develops targeted oncology therapies and leverages proprietary technology to address tumor resistance mechanisms. 
    Via The Motley Fool
    News headline image
    Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Hedge Fund Boone Capital Initiated a Stake in HealthEquity. Is the Stock a Buy? ↗
    HealthEquity delivers cloud-based healthcare savings solutions to employers and individuals, with a broad client network across the U.S. 
    Via The Motley Fool
    News headline image
    Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    13 14 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.